---
title: "美股盘前热门交易：Evoke Pharma 盘前跌 7.89%"
description: "Evoke Pharma 盘前跌 7.89%；GlucoTrack 盘前涨 73.06%；Helius Medical Tech 盘前涨 70.67%；reAlpha Tech 盘前涨 39.21%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/249410648.md"
published_at: "2025-07-21T12:27:41.000Z"
---

# 美股盘前热门交易：Evoke Pharma 盘前跌 7.89%

> Evoke Pharma 盘前跌 7.89%；GlucoTrack 盘前涨 73.06%；Helius Medical Tech 盘前涨 70.67%；reAlpha Tech 盘前涨 39.21%。

**美股盘前热门交易**  
Evoke Pharma 盘前跌 7.89%.基于近期重要新闻：  
1\. 7 月 9 日，Evoke Pharma 通过 EDGAR 发布信息，股价波动加剧。  
2\. 7 月 10 日，Evoke Pharma 获得 GIMOTI 新专利，股价上涨。  
3\. 近期，美国制药行业面临政策不确定性，影响股价。  
  
**美股盘前涨幅前列股票**  
GlucoTrack 盘前涨 73.06%.基于最近的关键新闻：  
1\. 6 月 25 日，GlucoTrack 宣布其新型无创血糖监测设备获得 FDA 批准，市场反应积极，股价大幅上涨。  
2\. 6 月 26 日，GlucoTrack 与大型医疗设备公司签署战略合作协议，进一步提升市场信心，推动股价继续上涨。  
3\. 6 月 27 日，知名分析师上调 GlucoTrack 目标价，预期其市场份额将大幅增加，股价应声上涨。  
  
Helius Medical Tech 盘前涨 70.67%.基于近期重要新闻：  
1\. 7 月 21 日，Helius 宣布其便携式神经调节刺激器 PONS®中风注册计划取得积极成果，并计划在 2025 年第三季度向 FDA 提交突破性指定申请，推动股价大幅上涨。  
2\. 7 月 21 日，Helius 确认 PONS 治疗的研究显示不良事件极少，增强了市场信心。  
3\. 7 月 21 日，Helius 计划提交 FDA 申请的消息进一步刺激了投资者的乐观情绪。  
  
reAlpha Tech 盘前涨 39.21%.基于最近的关键新闻：  
1\. 5 月 16 日，reAlpha Tech 宣布截至 3 月 31 日季度收入同比增长 4432%，股价大涨。  
2\. 7 月 16 日，reAlpha Tech 宣布 200 万美元公开募股，股价下跌 25.7%。  
3\. 7 月 17 日，reAlpha Tech 公开募股定价为每股 0.15 美元，股价继续下跌。

### Related Stocks

- [EVOK.US - Evoke Pharma](https://longbridge.com/zh-CN/quote/EVOK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Debt-laden William Hill UK owner Evoke explores sale after gambling tax hike | Evoke, owner of William Hill UK, is exploring a sale after UK tax hikes on online gaming and sports betting. The company | [Link](https://longbridge.com/zh-CN/news/269233994.md) |
| 10% Owner Roger M. Klein Sells Common Shares of Evoke Pharma Inc | Roger M. Klein, a 10% owner of Evoke Pharma Inc., has sold common shares of the company. The full filing is available th | [Link](https://longbridge.com/zh-CN/news/264933569.md) |
| Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025 | Evoke Pharma's Q3 2025 net product sales rose 61% year-over-year to $4.3 million. The company is set to be acquired by Q | [Link](https://longbridge.com/zh-CN/news/265721419.md) |
| Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical | Evoke Pharma has entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, represe | [Link](https://longbridge.com/zh-CN/news/264214043.md) |
| 11:28 ET
			
			
				Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders | The Ademi Firm is investigating Evoke Pharma Inc. (NASDAQ: EVOK) for potential breaches of fiduciary duty related to a r | [Link](https://longbridge.com/zh-CN/news/264262751.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
